<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069714</url>
  </required_header>
  <id_info>
    <org_study_id>2109-020-1252</org_study_id>
    <nct_id>NCT05069714</nct_id>
  </id_info>
  <brief_title>Effect of One-week vs Two-week Discontinuation of Methotrexate on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial</brief_title>
  <official_title>Effect of One-week vs Two-week Discontinuation of Methotrexate on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, single-blinded, prospective, parallel group intervention&#xD;
      study to investigate whether methotrexate (MTX) discontinuation for 1 week is non-inferior to&#xD;
      MTX discontinuation for 2 weeks in regard to satisfactory vaccination response to a seasonal&#xD;
      influenza.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
    <masking_description>Single-blinded study. Investigators assessing disease activity will be blinded to the treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of satisfactory vaccine response</measure>
    <time_frame>4 weeks</time_frame>
    <description>as ≥ 4-fold increase in post-vaccination titer in ≥ 2 of 4 influenza strains at 4 weeks after vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportio0n of patients who have ≥ 4-fold increase in post-vaccination titer in ≥ 3 of 4 influenza strains</measure>
    <time_frame>4 weeks and 16 weeks</time_frame>
    <description>Proportion of patients who have ≥ 4-fold increase in post-vaccination titer in ≥ 3 of 4 influenza strains at 4 weeks and 16 weeks after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of seroprotection for each strain</measure>
    <time_frame>4 weeks and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in titer (in GMT)</measure>
    <time_frame>4 weeks and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DAS28-4 (CRP)</measure>
    <time_frame>4 weeks and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease flare</measure>
    <time_frame>4 weeks and 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Influenza</condition>
  <condition>Vaccine Reaction</condition>
  <arm_group>
    <arm_group_label>MTX 1 week hold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who will hold MTX for 1 week after an influenza vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTX 2 week hold</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will hold MTX for 2 weeks after an influenza vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Temporary discontinuation of methotrexate for 1 week vs. 2 weeks</description>
    <arm_group_label>MTX 1 week hold</arm_group_label>
    <arm_group_label>MTX 2 week hold</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females ≥ 19 years of age at time of consent&#xD;
&#xD;
          -  Have a diagnosis of RA per ACR criteria&#xD;
&#xD;
          -  Must understand and voluntarily sign an informed consent form including writing&#xD;
             consent for data protection&#xD;
&#xD;
          -  Stable doses of methotrexate over the preceding 6 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Previous anaphylactic response to vaccine components or to egg.&#xD;
&#xD;
          -  Acute infection with T &gt;38°C at the time of vaccination&#xD;
&#xD;
          -  History of Guillain-Barre syndrome or demyelinating syndromes&#xD;
&#xD;
          -  Blood transfusion within 6 months&#xD;
&#xD;
          -  Any other rheumatic disease such as systemic lupus erythematosus, mixed connective&#xD;
             tissue disease, dermatomyositis/polymyositis, and vasculitis except for secondary&#xD;
             Sjogren's disease&#xD;
&#xD;
          -  Any condition including laboratory abnormality which places the subject at&#xD;
             unacceptable risk&#xD;
&#xD;
          -  Subjects who decline to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National Univ. Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Park JK, Kim MJ, Choi Y, Winthrop K, Song YW, Lee EB. Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials. Clin Rheumatol. 2020 Feb;39(2):375-379. doi: 10.1007/s10067-019-04857-y. Epub 2019 Dec 10.</citation>
    <PMID>31823141</PMID>
  </results_reference>
  <results_reference>
    <citation>Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018 Jun;77(6):898-904. doi: 10.1136/annrheumdis-2018-213222. Epub 2018 Mar 23.</citation>
    <PMID>29572291</PMID>
  </results_reference>
  <results_reference>
    <citation>Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017 Sep;76(9):1559-1565. doi: 10.1136/annrheumdis-2017-211128. Epub 2017 May 3.</citation>
    <PMID>28468794</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>methotrexate</keyword>
  <keyword>influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

